NeoGenomics shares rise to a 52-week high after the company received expanded Medicare coverage for its RaDaR ST liquid biopsy test.
https://finviz.com/stock?t=NEO&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.